Aptose Biosciences Inc (NAS:APTO)

$ 0.25 0.0012 (0.48%) Market Cap: 15.11 Mil Enterprise Value: 7.60 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 25/100

Q1 2024 Aptose Biosciences Inc Earnings Call Transcript
May 14, 2024

$1.23 (+4.24%)

Earnings
Q4 2023 Aptose Biosciences Inc Earnings Call Transcript
Mar 26, 2024

$1.6 (+5.96%)

Earnings
Q3 2023 Aptose Biosciences Inc Earnings Call Transcript
Nov 09, 2023

$3.24 (+5.88%)

Earnings
Aptose Biosciences Inc To Hold Clinical Update Call Transcript
Oct 30, 2023
Q2 2023 Aptose Biosciences Inc Earnings Call Transcript
Aug 10, 2023

$4 (+6.38%)

Earnings
Aptose Biosciences Inc To Discuss Clinical Update Call Transcript
Jun 10, 2023
Aptose Biosciences Inc Annual Shareholders Meeting Transcript
May 23, 2023
Aptose Biosciences Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 17, 2023
Q1 2023 Aptose Biosciences Inc Earnings Call Transcript
May 08, 2023

$7.95 (-1.85%)

Earnings
Q4 2022 Aptose Biosciences Inc Earnings Call Transcript
Mar 23, 2023

$8.55 (-2.55%)

Earnings
Aptose Biosciences Inc Corporate Update Call Transcript
Dec 11, 2022
Q3 2022 Aptose Biosciences Inc Earnings Call Transcript
Nov 01, 2022

$7.48 (+8.32%)

Earnings
Q2 2022 Aptose Biosciences Inc Earnings Call Transcript
Aug 02, 2022

$10.68 (-2.53%)

Earnings
Aptose Biosciences Inc To Hold KOL Event And Corporate Update Call Transcript
Jun 02, 2022
Aptose Biosciences Inc Annual Shareholders Meeting Transcript
May 31, 2022
Aptose Biosciences Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 17, 2022
Q1 2022 Aptose Biosciences Inc Earnings Call Transcript
May 09, 2022

$16.8 (-2.61%)

Earnings
Q4 2021 Aptose Biosciences Inc Earnings Call Transcript
Mar 22, 2022

$19.2 (+4.07%)

Earnings
Aptose Biosciences Inc at Corporate Update Call Transcript
Dec 13, 2021
Q3 2021 Aptose Biosciences Inc Earnings Call Transcript
Nov 11, 2021

$36 (+0.42%)

Earnings
Aptose Biosciences Inc Corporate Update Call Transcript
Nov 04, 2021
Q2 2021 Aptose Biosciences Inc Earnings Call Transcript
Aug 03, 2021

$39.45 (-1.13%)

Earnings
Aptose Biosciences Inc Business Update Call Transcript
Jun 11, 2021
Aptose Biosciences Inc at Jefferies Healthcare Conference (Virtual) Transcript
Jun 02, 2021
Aptose Biosciences Inc Annual Shareholders Meeting Transcript
Jun 01, 2021
Q1 2021 Aptose Biosciences Inc Earnings Call Transcript
May 04, 2021

$82.35 (-1.61%)

Earnings
Q4 2020 Aptose Biosciences Inc Earnings Call Transcript
Mar 23, 2021

$55.05 (-5.90%)

Earnings
Aptose Biosciences Inc Data Call Transcript
Dec 06, 2020
Q3 2020 Aptose Biosciences Inc Earnings Call Transcript
Nov 10, 2020

$67.95 (+0.44%)

Earnings
Q2 2020 Aptose Biosciences Inc Earnings Call Transcript
Aug 04, 2020

$77.1 (-1.15%)

Earnings
Aptose Biosciences Inc Annual Shareholders Meeting Transcript
Jun 02, 2020
Q1 2020 Aptose Biosciences Inc Earnings Call Transcript
May 05, 2020

$106.65 (+4.25%)

Earnings
Q4 2019 Aptose Biosciences Inc Earnings Call Transcript
Mar 10, 2020

$106.2 (-3.28%)

Earnings
Aptose Biosciences Inc. - Special Call Transcript
Feb 05, 2020
Q3 2019 Aptose Biosciences Inc Earnings Call Transcript
Nov 05, 2019

$34.5 (-2.54%)

Earnings
Q2 2019 Aptose Biosciences Inc Earnings Call Transcript
Aug 06, 2019

$35.1 (+2.63%)

Earnings
Q1 2019 Aptose Biosciences Inc Earnings Call Transcript
May 07, 2019

$33.45 (-2.19%)

Earnings
Q4 2018 Aptose Biosciences Inc Earnings Call Transcript
Mar 12, 2019

$26.1 (+5.45%)

Earnings

Aptose Biosciences Inc To Hold Clinical Update Call Transcript

Oct 30, 2023 / 12:30PM GMT

Release Date Price: $2.75 (-13.52%)

Transcript 10-Q8-K

Operator

Good afternoon. I would like to welcome everyone to the Aptose Biosciences' clinical update and data review in conjunction with the European School of Hematology, ESH 6th International Conference. (Operator Instructions) After the speakers' remarks, there will be a question-and-answer session.

Joining me on today's call are Dr. William Rice, Chairman and CEO; Dr. Rafael Bejar, Senior Vice President, Chief Medical Officer; and our special guest and key opinion leader, Dr. Naval Daver from the MD Anderson Cancer Center.

I will now turn the call over to Dr. Rice, Chairman and CEO of Aptose Biosciences. Please go ahead.

William Rice

Aptose Biosciences Inc. - Chairman, President & CEO

Thank you. Good morning, all. Today, we'll come to you from the European School of Haematology Conference being held in Estoril, Portugal. It's my pleasure to welcome you to our clinical update and KOL data review for Aptose's lead agent Tuspetinib that's being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia or AML. And

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.